Parkinson's Disease Clinical Trial
Official title:
Distinguishing Between Alzheimer's Disease, Lewy Body Dementia, and Parkinson's Disease
NCT number | NCT03019757 |
Other study ID # | 2014H0415 |
Secondary ID | |
Status | Recruiting |
Phase | |
First received | |
Last updated | |
Start date | August 30, 2018 |
Est. completion date | December 2024 |
The study is designed to characterize the clinical, neuropsychological, polysomnographic, and neuroimaging findings among subjects with Alzheimer's disease, Lewy Body dementia, and Parkinsons' Disease.
Status | Recruiting |
Enrollment | 76 |
Est. completion date | December 2024 |
Est. primary completion date | December 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Subjects must meet the standard clinical criteria of the syndromes of interest - All subjects must have enough cognitive abilities to complete study procedures, which will be operationally defined as having a Mini Mental State Examination (MMSE) score greater or equal to 10. - Subjects must be on stable cognitive and psychoactive medication regimen for the preceding four weeks of enrollment. - Subjects must have a responsible study partner that either lives with them or is in regular contact with them at least 4 out of 7 days per week. - Subjects must have visual and auditory acuity adequate for testing. Exclusion Criteria: - Any other condition (other than the primary diagnosis), which in the opinion of the investigators might contribute to the syndrome of dementia or complicate its assessment. - active medical disorder that could preclude participation in this protocol - Women who are pregnant or are breast feeding - severe renal impairment as defined by glomerular filtration rate (GFR) less than 30 (may have increased radiation exposure with the DaTscan). - Subjects in whom English is not the 1st language - Subjects with educational level less than 12 years - Subjects who have ever participated in an experimental study with an amyloid targeting agent unless it can be documented that the subject received only placebo during the course of the trial. |
Country | Name | City | State |
---|---|---|---|
United States | The Ohio State University | Columbus | Ohio |
Lead Sponsor | Collaborator |
---|---|
Douglas Scharre | Avid Radiopharmaceuticals, Mangurian Foundation |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Lumbar Puncture to obtain cerebrospinal fluid (CSF) that will be stored for future potential evaluation of biomarkers | Optional outcome measure which will be done to obtain samples of CSF | Baseline | |
Other | Post-mortem brain donation to The Ohio State University Neurodegenerative Disease Brain Tissue Repository, for clinicopathological correlations | Optional outcome measure for patients post-mortem to asses for neuropathologic conditions | Post mortem | |
Primary | Mini Mental State Examination (MMSE-1) | Global neuropsychological measure | Baseline | |
Primary | Wechsler Adult Intelligence Scale 4th edition (WAIS-4) Vocabulary | Neuropsychological measure of premorbid IQ estimate | Baseline | |
Primary | Wechsler Adult Intelligence Scale 4th edition (WAIS-4) Digit Span | Neuropsychological measure of attention | Baseline | |
Primary | Wechsler Adult Intelligence Scale 4th edition (WAIS-4) Block Design | Neuropsychological measure of visuospatial perception/ reasoning | Baseline | |
Primary | Wechsler Adult Intelligence Scale 4th edition (WAIS-4) Matrix Reasoning | Neuropsychological measure of executive functioning | Baseline | |
Primary | Wechsler Adult Intelligence Scale 4th edition (WAIS-4) Reliable Digits (embedded measure) | Neuropsychological measure of effort | Baseline | |
Primary | Wechsler Memory Scale 3rd ed. (WAIS-3) Spatial Span | Neuropsychological measure of attention | Baseline | |
Primary | Wechsler Memory Scale 3rd ed. (WAIS-3) Logical Memory 1 & 2 | Neuropsychological measure of memory | Baseline | |
Primary | Trail Making Test A | Neuropsychological measure of executive functioning/psychomotor processing speed | Baseline | |
Primary | Trail Making Test B | Neuropsychological measure of executive functioning | Baseline | |
Primary | Boston Naming Test | Neuropsychological measure of language | Baseline | |
Primary | Controlled Oral Word Association Test (COWAT)- Animal Naming | Neuropsychological measure of language/verbal fluency | Baseline | |
Primary | Judgment of Line Orientation Standardized Test | Neuropsychological measure of visuospatial perception/ reasoning | Baseline | |
Primary | Brief Visuospatial Memory Test (BVMT) | Neuropsychological measure of memory | Baseline | |
Primary | California Verbal Learning Test (CVLT-2) | Neuropsychological measure of memory | Baseline | |
Primary | Wisconsin Card Sorting Task | Neuropsychological measure of executive functioning | Baseline | |
Primary | California Verbal Learning Test (CVLT-2) Forced Choice (embedded measure) | Neuropsychological measure of effort | Baseline | |
Primary | Self Administered Gerocognitive Examination- A brief cognitive assessment instrument for mild cognitive impairment and early dementia | Global neuropsychological measure | Baseline | |
Primary | Apolipoprotein E (APOE) Genotyping of a whole blood sample | 10 ml of whole blood will be drawn for APOE genotyping | Baseline | |
Primary | Clinical Dementia Rating Scale (CDR) | Global cognitive and functional measure | Baseline | |
Primary | The Activities of Daily Living (ADL) Standardized Scale | Functional measure | Baseline | |
Primary | Mayo Fluctuations Scale | Behavioral measure | Baseline | |
Primary | Neuropsychiatric Inventory (NPI) | Behavioral measure | Baseline | |
Primary | Beck Depression Inventory 2nd ed. | Behavioral measure | Baseline | |
Primary | The Modified Somatic Perception Questionnaire | Behavioral measure | Baseline | |
Primary | The Epworth Sleepiness Scale | Sleep measure | Baseline | |
Primary | Mayo Sleep Questionnaire-Informant | Sleep measure | Baseline | |
Primary | Functional Outcomes of Sleep Questionnaire-10 | Sleep measure | Baseline | |
Primary | Part III and IV of the Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) | Gait, Mobility, and Coordination Measure | Baseline | |
Primary | Berg Balance Scale (BBS) | Gait, Mobility, and Coordination Measure | Baseline | |
Primary | Florbetapir (F18-AV-45) positron emission tomography (amyloid PET) | Imaging to determine extent of amyloid deposition | Baseline | |
Primary | Single-photon emission computed tomography (SPECT) with the radioligand [123I]FP-CIT | Functional imaging of the dopamine transporter | Baseline | |
Primary | Positron emission tomography with 2-(18F) fluoro-2-deoxy-d-glucose (FDG-PET) | Imaging to determine total and regional cerebral glucose metabolism | Baseline | |
Primary | Brain MRI | Imaging including a resting state functional MRI, diffusion tensor imaging, and anatomic imaging | Baseline | |
Primary | Polysomnogram | participants will have an overnight standard clinical polysomnogram with added limb leads assessing for presence of sleep apnea, periodic limb movements, and rapid eye movement (REM) sleep characteristics | Baseline |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02915848 -
Long-term Stability of LFP Recorded From the STN and the Effects of DBS
|
||
Recruiting |
NCT03648905 -
Clinical Laboratory Evaluation of Chronic Autonomic Failure
|
||
Terminated |
NCT02688465 -
Effect of an Apomorphine Pump on the Quality of Sleep in Parkinson's Disease Patients (POMPRENELLE).
|
Phase 4 | |
Completed |
NCT05040048 -
Taxonomy of Neurodegenerative Diseases : Observational Study in Alzheimer's Disease and Parkinson's Disease
|
||
Active, not recruiting |
NCT04006210 -
Efficacy, Safety and Tolerability Study of ND0612 vs. Oral Immediate Release Levodopa/Carbidopa (IR-LD/CD) in Subjects With Parkinson's Disease Experiencing Motor Fluctuations
|
Phase 3 | |
Completed |
NCT02562768 -
A Study of LY3154207 in Healthy Participants and Participants With Parkinson's Disease
|
Phase 1 | |
Completed |
NCT00105508 -
Sarizotan HC1 in Patients With Parkinson's Disease Suffering From Treatment-associated Dyskinesia
|
Phase 3 | |
Completed |
NCT00105521 -
Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia
|
Phase 3 | |
Recruiting |
NCT06002581 -
Repetitive Transcranial Magnetic Stimulation(rTMS) Regulating Slow-wave to Delay the Progression of Parkinson's Disease
|
N/A | |
Completed |
NCT02236260 -
Evaluation of the Benefit Provided by Acupuncture During a Surgery of Deep Brain Stimulation
|
N/A | |
Completed |
NCT00529724 -
Body Weight Gain, Parkinson, Subthalamic Stimulation
|
Phase 2 | |
Active, not recruiting |
NCT05699460 -
Pre-Gene Therapy Study in Parkinson's Disease and Multiple System Atrophy
|
||
Completed |
NCT03703570 -
A Study of KW-6356 in Patients With Parkinson's Disease on Treatment With Levodopa-containing Preparations
|
Phase 2 | |
Completed |
NCT03462680 -
GPR109A and Parkinson's Disease: Role of Niacin in Outcome Measures
|
N/A | |
Completed |
NCT02837172 -
Diagnosis of PD and PD Progression Using DWI
|
||
Not yet recruiting |
NCT04046276 -
Intensity of Aerobic Training and Neuroprotection in Parkinson's Disease
|
N/A | |
Recruiting |
NCT02952391 -
Assessing Cholinergic Innervation in Parkinson's Disease Using the PET Imaging Marker [18F]Fluoroethoxybenzovesamicol
|
N/A | |
Active, not recruiting |
NCT02937324 -
The CloudUPDRS Smartphone Software in Parkinson's Study.
|
N/A | |
Terminated |
NCT02894567 -
Evaluation of Directional Recording and Stimulation Using spiderSTN
|
N/A | |
Completed |
NCT02874274 -
Vaccination Uptake (VAX) in PD
|
N/A |